173 related articles for article (PubMed ID: 30879557)
1. Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation.
Papachristou M; Fylaktou A; Daoudaki M; Cholongitas E; Karampatakis T; Anastasiou A; Chatzika G; Makrovasili F; Vagiotas L; Karakasi K; Fouzas I
Transplant Proc; 2019 Mar; 51(2):424-428. PubMed ID: 30879557
[TBL] [Abstract][Full Text] [Related]
2. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
[TBL] [Abstract][Full Text] [Related]
3. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
4. Anti-human leukocyte antigen immunization after early allograft nephrectomy.
Del Bello A; Congy N; Sallusto F; Cardeau-Desangles I; Fort M; Esposito L; Guitard J; Cointault O; Lavayssière L; Nogier MB; Game X; Blancher A; Rostaing L; Kamar N
Transplantation; 2012 May; 93(9):936-41. PubMed ID: 22361471
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients.
Del Bello A; Congy-Jolivet N; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Suc B; Duffas JP; Alric L; Bureau C; Danjoux M; Guilbeau-Frugier C; Blancher A; Rostaing L; Kamar N
Am J Transplant; 2014 Apr; 14(4):867-75. PubMed ID: 24580771
[TBL] [Abstract][Full Text] [Related]
6. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
[TBL] [Abstract][Full Text] [Related]
8. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
9. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation.
Musat AI; Pigott CM; Ellis TM; Agni RM; Leverson GE; Powell AJ; Richards KR; D'Alessandro AM; Lucey MR
Liver Transpl; 2013 Oct; 19(10):1132-41. PubMed ID: 23873778
[TBL] [Abstract][Full Text] [Related]
10. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
12. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
13. Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients.
Levitsky J; Kaneku H; Jie C; Walsh RC; Abecassis M; Tambur AR
Am J Transplant; 2016 Aug; 16(8):2437-44. PubMed ID: 26896194
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
[TBL] [Abstract][Full Text] [Related]
15. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
16.
Beyzaei Z; Geramizadeh B; Bagheri Z; Karimzadeh S; Shojazadeh A
Front Immunol; 2020; 11():613128. PubMed ID: 33424868
[TBL] [Abstract][Full Text] [Related]
17. Human Leukocyte Antigen Compatibility and De Novo Donor-Specific Antibodies in Long-term Renal Transplant Patients With Stable Graft Function.
Kasimatis E; Fylaktou A; Karampatakis T; Schoina M; Zarras C; Anastasiou A; Papachristou M; Boukla A; Daoudaki M; Fouzas I; Papagianni A
Transplant Proc; 2019 Mar; 51(2):413-415. PubMed ID: 30879554
[TBL] [Abstract][Full Text] [Related]
18. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
[TBL] [Abstract][Full Text] [Related]
19. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.
Bouquegneau A; Loheac C; Aubert O; Bouatou Y; Viglietti D; Empana JP; Ulloa C; Murad MH; Legendre C; Glotz D; Jackson AM; Zeevi A; Schaub S; Taupin JL; Reed EF; Friedewald JJ; Tyan DB; Süsal C; Shapiro R; Woodle ES; Hidalgo LG; O'Leary J; Montgomery RA; Kobashigawa J; Jouven X; Jabre P; Lefaucheur C; Loupy A
PLoS Med; 2018 May; 15(5):e1002572. PubMed ID: 29799874
[TBL] [Abstract][Full Text] [Related]
20. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
